

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07C 323/59, 235/40, 233/63		(11) International Publication Number: WO 91/07386
		A1 (43) International Publication Date: 30 May 1991 (30.05.91)
<p>(21) International Application Number: PCT/US90/06655</p> <p>(22) International Filing Date: 20 November 1990 (20.11.90)</p> <p>(30) Priority data: 439,765 21 November 1989 (21.11.89) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 439,765 (CIP) Filed on 21 November 1989 (21.11.89)</p> <p>(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : NEUSTADT, Bernard, R. [US/US]; 24 Brook Place, West Orange, NJ 07052 (US). SMITH, Elizabeth, M. [CA/US]; 166 Grove Avenue, Verona, NJ 07044 (US). HASLANGER, Martin, F. [US/US]; 53 West Glen Avenue, Ridgewood, NJ 07450 (US).</p>		
<p>(74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, One Giralta Farms, Madison, NJ 07940-1000 (US).</p> <p>(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published With international search report. With amended claims.</p>		

(54) Title: CARBOXYALKYLCARBONYL AMINOACID ENDOPEPTIDASE INHIBITORS



(57) Abstract

Carboxyalkylcarbonyl aminoacid inhibitors of endopeptidases of formula (I), or pharmaceutically acceptable salt thereof, wherein R¹ is H, alkyl, arylalkyl, aryl or aryloxyalkyl; R² is alkyl, alkenyl, alkynyl, alkoxy or alkylthio, wherein the alkyl portion is substituted with 0-3 substituents independently selected from the group consisting of hydroxy, alkoxy, alkoxyalkoxy, alkylthio, aryl, alkoxyalkylthio, arylalkoxy and arylalkylthio; R³ and R⁴ are independently alkyl or arylalkyl; or R³ and R⁴ together with the carbon to which they are attached form an optionally substituted 5-, 6- or 7-membered ring wherein said ring comprises 0 to 1 heteroatoms selected from the group consisting of sulfur and oxygen; R⁵ is H, alkyl, alkoxyalkyl, alkylthioalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylalkoxyalkyl or arylalkylthioalkyl; R⁶ is H, hydroxy, alkoxy, alkyl, arylalkoxy, alkoxyalkyl, alkylthioalkyl, arylalkoxyalkyl, arylalkylthioalkyl, aryl or heteroaryl; R⁷ is hydroxy, alkoxy, aryloxy, arylalkoxy, amino, alkylamino or dialkylamino; m is 0 or 1; and n is 0, 1, 2 or 3, use of the compounds, alone or in combination with an ACE inhibitor or an ANF, in the treatment of cardiovascular disorders such as hypertension, congestive heart failure, edema and renal insufficiency, use of the compounds in the treatment of nephrotoxicity and pain conditions, and pharmaceutical compositions containing said compounds are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MC	Madagascar		
ES	Spain				

CARBOXYALKYLCARBONYL AMINOACID
ENDOPEPTIDASE INHIBITORS

BACKGROUND OF THE INVENTION

The present invention relates to carboxyalkyl-carbonyl aminoacid inhibitors of endopeptidases useful in the treatment of cardiovascular disorders, nephrotoxicity and pain conditions.

Cardiovascular conditions which may be treated with compounds of the present invention include hypertension, congestive heart failure, edema and renal insufficiency. Nephrotoxicity resulting from immunosuppression therapy may also be treated with compounds of this invention.


Human hypertension is a disease of multiple etiologies. Included among these is a sodium and volume dependent low renin form of hypertension. Drugs that act to control one aspect of hypertension will not necessarily be effective in controlling another.

Enkephalin is a natural opiate receptor agonist which is known to produce a profound analgesia when injected into the brain ventricle of rats. Enkephalin is known to be inactivated by a group of naturally occurring enzymes known as enkephalinases or endopeptidases.

A variety of compounds known as endopeptidase inhibitors are useful as analgesics and/or in the


-2-

treatment of hypertension. For example, European Patent Application 274,234 discloses, inter alia, spiro-substituted glutaramide diuretic compounds of the formula




wherein R^5 may be a variety of alkyl or amino derivatives or a heterocycle. European Patent Application 358,398 discloses similar compounds wherein the carboxy-substituted cycloalkylamino group is replaced by a substituted alanyl group, e.g. phenylalanyl.

European Patent Application 38,046 discloses, inter alia, enkephalinase inhibitors of the formula



wherein R^2 is lower alkyl or methylthiomethyl and Ph is optionally substituted phenyl.


U.S. Patent 4,513,009 discloses, inter alia, alpha amino acid derivatives of the formula



wherein R^1 is preferably hydrogen or phenyl and R^2 is preferably hydrogen, alkyl, benzyl or benzyloxyalkyl. The compounds are said to have enkephalinase inhibiting and hypotensive activity.


-3-

U.S. Patent 4,939,261 discloses enkephalinase inhibitory N-substituted butyramide derivatives of the formula




wherein R^1 and R^2 are alkyl or arylalkyl and A is alkylene, substituted alkylene, phenylene or cyclohexylene.

U.S. Patent 4,610,816 discloses, inter alia, substituted dipeptide enkephalinase inhibitors of the formula



wherein R^1 and R^3 are preferably phenylethyl and R^4 is preferably hydrogen, methyl or benzyl.

Similarly, German Patent Application 3,819,539 discloses, inter alia, carboxyalkyl compounds of the formula



wherein R_1 and R_8 are preferably benzyl and R_5 is preferably hydrogen or lower alkyl.

It has recently been discovered that the heart secretes a series of peptide hormones called atrial natriuretic factors (ANF) which help to regulate blood pressure, blood volume and the excretion of water, sodium and potassium. ANF were found to produce a short-term reduction in blood pressure and to be useful in the treatment of congestive heart failure. See P. Needleman


-4-

et al, "Atriopeptin: A Cardiac Hormone Intimately Involved in Fluid, Electrolyte and Blood-Pressure Homostasis", N. Engl. J. Med., 314, 13 (1986) pp. 828-834, and M. Cantin et al in "The Heart as an Endocrine Gland", Scientific American, 254 (1986) pg. 76-81.

Angiotensin converting enzyme (ACE) inhibitors are another class of drugs known to be effective in treating some types of hypertension. ACE inhibitors are useful in blocking the rise in blood pressure caused by increases in vascular resistance and fluid volume due to the formation of angiotensin II from angiotensin I. For a review of ACE inhibitors, see M. Wyvratt et al., "Recent Developments in the Design of Angiotensin Converting Enzyme Inhibitors" in Med. Res. Rev., 5, No. 4 (1985) pp. 483-531.

SUMMARY OF THE INVENTION

Novel compounds of the present invention are represented by the formula



wherein R^1 is H, alkyl, arylalkyl, aryl or aryloxyalkyl; R^2 is alkyl, alkenyl, alkynyl, alkoxy or alkylthio, wherein the alkyl portion is substituted with 0-3 substituents independently selected from the group consisting of hydroxy, alkoxy, alkoxyalkoxy, alkylthio, aryl, alkoxyalkylthio, arylalkoxy and arylalkylthio;

R^3 and R^4 are independently alkyl or arylalkyl; or R^3 and R^4 together with the carbon to which they are attached form a 5-, 6- or 7-membered ring wherein said ring comprises 0 to 1 heteroatoms selected from the group

-5-

consisting of sulfur and oxygen, wherein said ring is unsubstituted or is substituted on a carbon atom ring member by an alkyl or aryl group, or wherein said ring is substituted by a fused benzene ring;

R^5 is H, alkyl, alkoxyalkyl, alkylthioalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylalkoxyalkyl or arylalkylthioalkyl;

R^6 is H, hydroxy, alkoxy, alkyl, arylalkoxy, alkoxyalkyl, alkylthioalkyl, arylalkoxyalkyl, arylalkylthioalkyl, aryl or heteroaryl;

R^7 is hydroxy, alkoxy, aryloxy, arylalkoxy, amino, alkylamino or dialkylamino;

m is 0 or 1;

n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

A preferred group of compounds of the present invention is that wherein R^2 is arylalkyl, especially phenylethyl, or alkoxyalkoxyalkyl, especially methoxyethoxymethyl. Another preferred group is that wherein R^3 and R^4 together with the carbon to which they are attached form a 5-, 6- or 7-membered ring, especially a carbocyclic ring; especially preferred is a 5-membered ring. Still another preferred group is that wherein R^5 is hydrogen, R^6 is hydroxy or hydrogen, m is 1 and n is zero. Also preferred are compounds wherein R^6 is alkylthioalkyl and m and n are each zero; an especially preferred alkylthioalkyl group is methylthioethyl.

Other preferred compounds of formula I are those wherein R^1 is hydrogen. R^7 is preferably hydroxy, ethoxy or benzyloxy.

The invention also relates to the treatment of cardiovascular diseases or nephrotoxicity with a combination of a carboxyalkylcarbonyl aminoacid of the present invention and an atrial natriuretic factor (ANF) or with a combination of a carboxyalkylcarbonyl aminoacid

-6-

of the present invention and an angiotensin converting enzyme (ACE) inhibitor.

Other aspects of the invention relate to pharmaceutical compositions comprising a carboxyalkylcarbonyl aminoacid of this invention, alone or in combination with an ANF or an ACE inhibitor, and to methods of treatment of cardiovascular diseases comprising administering a carboxyalkylcarbonyl aminoacid of this invention, alone or in combination with an ANF or an ACE inhibitor, to a mammal in need of such treatment.

Still another aspect of this invention relates to a method of treating pain conditions by administering a carboxyalkylcarbonyl aminoacid of this invention, thereby inhibiting the action of endopeptidases in a mammal and eliciting an analgesic effect. Analgesic pharmaceutical compositions comprising said carboxyalkylcarbonyl aminoacid compounds are also contemplated.

DETAILED DESCRIPTION

As used herein, the term "alkyl" means straight or branched lower alkyl chains of 1 to 6 carbon atoms; "alkenyl" similarly means lower alkenyl chains of 2 to 6 carbon atoms; "alkynyl" means lower alkynyl chains of 2 to 6 carbon atoms; and "alkoxy" similarly means lower alkoxy chains of 1 to 6 carbon atoms.

"Aryl" means a phenyl or naphthyl ring; a phenyl or naphthyl ring substituted with 1-3 substituents selected from the group consisting of alkyl, hydroxy, alkoxy, halo, trifluoromethyl, phenyl, phenoxy and phenylthio; or a phenyl ring wherein adjacent alkyl or alkyl and alkoxy substituents form a 5- or 6-membered ring (for example indanyl, dihydrobenzofuranyl, 1,2,3,4-tetrahydronaphthyl and isochromanyl).

-7-

"Heteroaryl" means mono-cyclic or fused ring bicyclic aromatic groups having 5 to 10 ring members wherein 1-2 ring members are independently selected from the group consisting of oxygen, nitrogen and sulfur and wherein 1-3 carbon ring members may be substituted with substituents as defined above for aryl. Examples of heteroaryl groups are furanyl, thienyl, pyrrolyl, benzofuranyl, thianaphthenyl, indolyl and pyridyl.

All positional isomers of the aryl and heteroaryl groups are contemplated, e.g. 2-pyridyl and 3-pyridyl, α -naphthyl and β -naphthyl.

Halo means fluoro, chloro, bromo or iodo radicals.

Certain compounds of the invention are acidic e.g., those compounds which possess a carboxyl group. These compounds form pharmaceutically acceptable salts with inorganic and organic bases. Examples of such salts are the sodium, potassium, calcium and aluminum salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxy alkyl amines, N-methylglucamine and the like.

The salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the cations of an existing salt for another cation on a suitable ion exchange resin.

Compounds of formula I have at least one asymmetrical carbon atom and therefore include various stereoisomers. The invention includes all such isomers both in pure form and in admixture, including racemic mixtures.

-8-

An aspect of the present invention described above relates to the combination of a compound of formula I with an ANF. As indicated by Needleman et al., a number of ANF have been isolated so far, all having the same core sequence of 17 amino acids within a cysteine disulfide bridge, but having different N-termini lengths. These peptides represent N-terminal truncated fragments (21-48 amino acids) of a common preprohormone (151 and 152 amino acids for man and rats, respectively). Human, porcine and bovine carboxy-terminal 28-amino acid peptides are identical and differ from similar peptides in rats and mice in that the former contain a methionine group at position 12 while the latter contain isoleucine. Various synthetic analogs of naturally occurring ANF's also have been found to have comparable biological activity. Examples of ANF's contemplated for use in this invention are α human AP 21 (atriopeptin I), α human AP 28, α human AP 23 (atriopeptin II or APII), α human AP 24, α human AP 25, α human AP 26, α human AP 33, and the corresponding rat sequence of each of the above wherein Met 12 is Ile. See Table 1 for a comparison of the peptides.

TABLE I

HUMAN
PEPTIDE

	* * *
AP 33	LAGPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY
AP 28	SLRRSSCFGGRMDRIGAQSGLGCNSFRY
AP 26	RRSSCFGGRMDRIGAQSGLGCNSFRY
AP 25	RSSCFGGRMDRIGAQSGLGCNSFRY
AP 24	SSCFGGRMDRIGAQSGLGCNSFRY
AP 23	SSCFGGRMDRIGAQSGLGCNSFR
AP 21	SSCFGGRMDRIGAQSGLGCNS

where the amino acids are designated by their single-letter abbreviations, namely

A Ala	Alanine	M Met	Methionine
C Cys	Cysteine	N Asn	Asparagine
D Asp	Aspartic acid	P Pro	Proline

-9-


F	Phe	Phenylalanine	Q	Gln	Glutamine
G	Gly	Glycine	R	Arg	Arginine
I	Ile	Isoleucine	S	Ser	Serine
L	Leu	Leucine	Y	Tyr	Tyrosine;

M* is replaced by I (Ile), in the rat peptide; and the two C* (Cys) residues are connected by a disulfide bridge.

Another aspect of the invention is the administration of a combination of an ACE inhibitor and a compound of formula I.

Examples of ACE inhibitors are those disclosed in the article by Wyvratt et al., cited above, and in the following U.S. patents: U.S. Patents 4,105,776, 4,468,519, 4,555,506, 4,374,829, 4,462,943, 4,470,973, 4,470,972, 4,350,704, 4,256,761, 4,344,949, 4,508,729, 4,512,924, 4,410,520 and 4,374,847, all incorporated herein by reference; and the following foreign patents or published patent applications:

British Specification No. 2095682 published October 6, 1982 discloses N-substituted-N-carboxyalkylcarbonyl amino carboxyl alkyl glycine derivatives which are said to be angiotensin converting enzyme inhibitors and have the formula



either

(A) R^b and R_9^b are OH, 1-6C alkoxy, 2-6C alkonyloxy, di-(1-6C alkyl)amino-(1-6C) alkoxy, 1-6C hydroxy alkoxy, acylamino-(1-6C) alkoxy, acyloxy-(1-6C) alkoxy, aryloxy, aryloxy-(1-


-10-

6C) alkoxy, NH₂, mono- or di-(1-6C alkyl)amino, hydroxy amino or aryl-(1-6C)alkylamino; R₁^b-R₅^b, R₇^b and R₈^b are 1-20C alkyl, 2-20C alkonyl, 2-20C alkynyl, aryl, aryl-(1-6C) alkyl having 7-12C or heterocyclyl-(1-6C)alkyl having 7-12C; R₆^b is cycloalkyl, polycycloalkyl, partly saturated cycloalkyl or polycycloalkyl, cycloalkyl-(1-6C)alkyl having 3-20C, 6-10C aryl, aryl-(1-6C)alkyl, aryl-(2-6C)alkenyl or aryl-(2-6C) alkynyl; or R₂^b and R₃^b together with the C and N atoms to which they are attached or R₃^b and R₅^b together with the N and C atoms to which they are attached form an N-heterocycle containing 3-5C or 2-4C and a S atom; all alkyl, alkonyl and alkynyl are optionally substituted by OH, 1-6C alkoxy, thio(sic), 1-6C alkylthio, NH₂, mono- or di(1-6C alkyl)amino, halogen or NO₂; all 'cycloalkyl' groups (including poly and partially unsaturated) are optionally substituted by halogen, 1-6C hydroxy alkyl, 1-6C alkoxy, amino-(1-6C alkyl)amino, di-(1-6C alkyl)amino, SH, 1-6C alkylthio, NO₂ or CF₃; and aryl groups are optionally substituted by OH, 1-6C alkoxy, NH₂, mono- or di-(1-6C alkyl)amino, SH, 1-6C alkylthio, 1-6C hydroxy alkyl, 1-6C aminoalkyl, 1-6C thioalkyl, NO₂, halogen, CF₃, OCH₂O, ureido or guanidino; or (B) R^b and R₉^b are H or 1-6C alkoxy; R₁^b and R₂^b are H, 1-6C alkyl, aryl-(1-6C) alkyl having 7-12C or heterocyclyl-(1-6C) alkyl having 6-12C;

-11-

R_3^b and R_5^b , R_7^b and R_8^b are H or 1-6C alkyl; R_6^b is cycloalkyl, polycycloalkyl, partly saturated cycloalkyl or polycycloalkyl, cycloalkyl-(1-6C) alkyl having 3-20C, aryl or aryl-(1-6C) alkyl; and aryl has 6-10C and is optionally substituted by 1-6C alkyl, 2-6C alkonyl, 2-6C alkynyl, OH, 1-6C alkoxy, NH_2 , mono- or di-(1-6C alkyl) amino, SH, 1-6C alkylthio, 1-6C hydroxy alkyl, 1-6C aminoalkyl, 1-6C thioalkyl, NO_2 , halogen, CF_3 , OCH_2O , ureido or guanidino;


European Patent Application 0 050 800 published May 5, 1982 discloses carboxy alkyl dipeptides derivatives which are said to be angiotensin converting enzyme inhibitors and have the formula



or a pharmaceutically acceptable salt thereof, wherein R^C and R^{6C} are the same or different and are hydroxy, lower alkoxy, lower alkonyloxy, dilower alkylamino lower alkoxy, acylamino lower alkoxy, acyloxy lower alkoxy, aryloxy, aryllower alkoxy, amino, lower alkylamino, dilower alkylamino, hydroxy amino, aryllower alkylamino, or substituted aryloxy or substituted aryllower alkoxy wherein the substituent is methyl, halo or methoxy; R^{1C} is hydrogen, alkyl of from 1 to 10 carbon atoms, substituted lower alkyl wherein the substituent is hydroxy, lower alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, amino, lower alkylamino, diloweralkylamino, acylamino, arylamino,

-12-

substituted arylamino, guanidino, imidazolyl, indolyl, lower alkylthio, arylthio, substituted arylthio, carboxy, carbamoyl, lower alkoxy carboxyl, aryl, substituted aryl, aralkyloxy, substituted aralkyloxy, aralkylthio or substituted aralkylthio, wherein the aryl or heteroaryl portion of said substituted aryloxy, heteroaryloxy, arylamino, arylthio, aryl, aralkyloxy, aralkylthio group is substituted with a group selected from halo, lower alkyl, hydroxy, lower alkoxy, amino, aminomethyl, carboxyl, cyano, or sulfamoyl; R^{2c} and R^{7c} are the same or different and are hydrogen or lower alkyl; R^{3c} is hydrogen, lower alkyl, phenyl lower alkyl, aminoethylphenyl lower alkyl, hydroxyphenyl lower alkyl, hydroxy lower alkyl, acylamino lower alkyl, amino lower alkyl, dimethylamino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, or lower alkyl thio lower alkyl; R^{4c} and R^{5c} are the same or different and are hydrogen, lower alkyl or Z^c , or R^{4c} and R^{5c} taken together form a group represented by Q^c , U^c , V^c , Y^c , D^c or E^c , wherein; Z^c is




wherein X^{1c} and X^{2c} independent of each other are O, S or CH_2 , R^{8c} and R^{9c} independent of each other are lower alkyl, lower alkonyl, lower alkynyl, cycloalkyl having 3 to 8 carbon atoms, hydroxy lower alkyl, or $-(CH_2)_n^c Ar^c$, wherein n^c is 0, 1, 2 or 3 and Ar^c is unsubstituted or substituted phenyl, furyl, thienyl or pyridyl, wherein said substituted phenyl, furyl, thienyl or pyridyl groups are substituted with at least one group that is

-13-


independently selected from C_1 to C_4 alkyl, lower alkoxy, lower alkylthio, halo, CF_3 and hydroxy, or R^{8C} and R^{9C} taken together form a bridge W^C , wherein W^C is a single bond or a methylene bridge or a substituted methylene bridge when at least one of X^{1C} and X^{2C} is methylene, or W^C is an alkylene or substituted alkylene bridge having 2 or 3 carbon atoms, said substituted methylene bridge or said substituted alkylene bridge having one or two substituents selected from lower alkyl, aryl and aryl lower alkyl groups, and p^C is 0, 1 or 2; with the proviso that at least one of R^{4C} and R^{5C} is Z^C , with the proviso that if R^{4C} is Z^C and p^C is 0 then X^{1C} and X^{2C} must both be methylene, and with the proviso that if X^{1C} and X^{2C} are both methylene then R^{8C} and R^{9C} must form an alkylene bridge W^C ;

Q^C is




wherein R^{8C} , R^{9C} , X^{1C} and X^{2C} are as defined above, p^C is 0, 1 or 2, q^C is 0, 1 or 2, with the proviso that the sum of p^C and q^C must be 1, 2 or 3, with the proviso that if p^C is 0 then X^{1C} and X^{2C} must be methylene, and with the proviso that if X^{1C} and X^{2C} are methylene then R^{8C} and R^{9C} taken together form a bridge W^C , wherein W^C is as defined above;

V^C is




-14-

wherein R^{8C} , R^{9C} , x^{1C} and x^{2C} are as defined above, p^C is 0, 1 or 2 and q^C is 0, 1 or 2, with the proviso that the sum of p^C and q^C is 1, 2 or 3, with the proviso that if x^{1C} and x^{2C} are CH_2 then R^{8C} and R^{9C} taken together form a bridge W^C , wherein W^C is as defined above; U^C is




wherein W^C is as defined above (except that W^C may also be a methylene bridge when x^{1C} and x^{2C} are oxygen or sulfur), x^{1C} and x^{2C} are as defined above, p^C is 0, 1 or 2, q^C is 0, 1 or 2, with the proviso that the sum of p^C and q^C is 1 or 2, and with the proviso that if p^C is 0, x^{1C} must be CH_2 ; U^C is




wherein G^C is oxygen, sulfur or CH_2 , a^C is 2, 3 or 4 and b^C is 1, 2, 3, 4 or 5, with the proviso that the sum of a^C and b^C is 5, 6 or 7 or G^C is CH_2 , a^C is 0, 1, 2 or 3, b^C is 0, 1, 2 or 3 with the proviso that the sum of a^C and b^C is 1, 2 or 3, with the proviso that the sum of a^C and b^C may be 1, 2 or 3 only if R^{1C} is lower alkyl substituted with aralkylthio or aralkyloxy;

-15-


 D^C is

wherein F^C is 0 or S, j^C is 0, 1 or 2 and k^C is 0, 1 or 2, with the proviso that the sum of j^C and k^C must be 1, 2 or 3, and m^C is 1, 2 or 3 and t^C is 1, 2 or 3, with the proviso that the sum of m^C and t^C must be 2, 3 or 4;
 E^C is




wherein L^C is 0 or S, u^C is 0, 1 or 2 and v^C is 0, 1 or 2, with the proviso that the sum of u^C and v^C must be 1 or 2, and h^C is 1 or 2 and s^C is 1 or 2, with the proviso that the sum of h^C and s^C must be 2 or 3;

European Patent Application 0 079 522 published May 25, 1983 discloses N-carboxymethyl(amidino) lysyl-proline compounds which are said to be angiotensin converting enzyme inhibitors and have the formula where





-16-



wherein:

R^d and R^{2d} are independently hydrogen; loweralkyl; aralkyl; or aryl; R^{1d} is hydrogen; branched or straight chain C_{1-12} alkyl and alkonyl; C_3-C_9 cycloalkyl and benzofused alkyl; substituted loweralkyl where the substituents are halo, hydroxy loweralkoxy, aryloxy, amino, mono- or diloweralkylamino, acylamino, arylamino, guanidino, mercapto, loweralkylthio, arylthio, carboxy, carboxamido, or loweralkoxycarbonyl; aryl; substituted aryl where the substituents are loweralkyl, loweralkoxy, or halo; arloweralkyl; arloweralkenyl; heteroarloweralkyl; heteroarloweralkenyl; substituted arloweralkyl, substituted arloweralkenyl, substituted heteroarloweralkyl, or substituted heteroarloweralkenyl where the aryl and heteroaryl substituents are halo, dihalo, loweralkyl, hydroxy, loweralkoxy, amino, aminoloweralkyl, acylamino, mono- or diloweralkylamino, carboxyl, haloloweralkyl, nitro, cyano, or sulfonamido, and where the loweralkyl portion of arloweralkyl may be substituted by amino, acylamino, or hydroxyl;

-17-



where:

X^d and Y^d taken together are $-CH_2-CH_2-$;

$-CH_2-S-$; $-C(=O)-CH_2-$; $-CH_2-C(=O)-$; $-C(=O)-O-$; $-C(=O)-S-$;

$-CH_2-CH_2-$; $-C(=O)-N-$; or $-CH_2-C(=O)-R^5d$;

R^4d is hydrogen; loweralkyl; aryl; substituted aryl;

R^5d is hydrogen; loweralkyl; aryl or substituted aryl;

n^d is 1 to 3;

W^d is absent; $-CH_2-$; or $-C(=O)-$;

Z^d is $-(CH_2)_m^d$, where m^d is 0 to 2, provided that m^d may not be 0 and W^d may not be absent at the same time; and

R^6d is hydrogen; loweralkyl; halo; or OR^4d ;

-18-

R^{2d} is $-(CH_2)_r^d-B^d-(CH_2)_s^d-NR^{7d}R^{15d}$


where

r^d and s^d are independently 0 to 3;

B^d is absent; $-O-$; $-S-$; or $-NR^{8d}$;

where R^{8d} is hydrogen; loweralkyl; alkanoyl; or aroyl; and

R^{7d} is



where

R^{9d} is loweralkyl; aralkyl; aryl; heteroaryl; or heteroarloweralkyl and these groups substituted by hydroxy, lower alkoxy or halo; carboxyl; carboxamido; nitromethenyl.

R^{10d} is

hydrogen; loweralkyl; aryl; or amidino;

R^{11d}

hydrogen; loweralkyl; cyano; amidino; aryl; aroyl; loweralkanoyl; $-C-NHR^{13d}$;

$\begin{array}{c} || \\ -C-OR^{13d}; -NO_2; -SO_2NH_2; \\ \parallel \\ O \end{array}$

or

SO_2R^{13d} ;

R^{12d} is


hydrogen; loweralkyl; halo; aralkyl; amino; cyano; mono- or diloweralkylamino; or OR^{4d} ;

R^{13d} is

hydrogen; loweralkyl; or aryl;

R^{15d} is

hydrogen; lower alkyl; aralkyl; or aryl;




constitute a basic heterocycle of 5 or 6 atoms or benzofused analogs thereof and optionally containing 1-3 N atoms, an oxygen, a sulfur, an

-19-

S=O, or an SO₂ group optionally substituted by amino, lower alkyl amino, diloweralkyl amino, lower alkoxy, or aralkyl groups;

R^{3d} is C_{3-8} cycloalkyl and benzofused C_{3-8} cycloalkyl; perhydrobenzofused C_{3-8} cycloalkyl; aryl; substituted aryl; heteraryl; substituted heteroaryl;
 R^{14d} is hydrogen or loweralkyl; and, a pharmaceutically acceptable salt thereof;

European Patent 79022 published May 18, 1983 discloses N-amino acyl-azabicyclooctane carboxylic acid derivatives which have the formula



hydrogen atoms at ring positions 1 and 5 are cis to each other and the 3-carboxy group has the endo orientation;

R_1^e is H, allyl, vinyl or the side chain of an optionally protected naturally occurring α -amino acid;


R_2^e is H, 1-6C alkyl, 2-6C alkonyl or aryl(1-4C alkyl);

y^e is H or OH and z^e is H, or y^e and z^e together oxygen;

X^e is 1-6C alkyl, 2-6C alkonyl, 5-9C cycloalkyl, 6-12C aryl (optionally substituted by one to three 1-4C alkyl or alkoxy, OH, halo, nitro, amino (optionally substituted by one or two 1-4C alkyl), or methylenedioxy) or indol-3-yl);

-20-

European Patent 46953 published March 10, 1982 discloses N-amino acyl-indoline and tetrahydro isoquinoline carboxylic acids which are angiotensin converting enzyme inhibitors and have the formula



n^f is 0 or 1;

A^f is a benzene or cyclohexane ring:

R_1^f and R_2^f are each 1-6C alkyl, 2-6C alkonyl, 5-7C cycloalkyl, 5-7C cycloalkenyl, 7-12C cycloalkylalkyl, optionally partially hydrogenated 6-10C aryl, 7-14C aralkyl or 5-7 membered monocyclic or 8-10 membered bicyclic heterocyclyl containing 1 or 2 S or O and/or 1-4N atoms; all R_1^f and R_2^f groups are optionally substituted,


R_3^f is H, 1-6C alkyl, 2-6C alkonyl or 7-14C aralkyl.

The following Table II lists ACE inhibitors preferred for use in the combination of this invention.

TABLE II
PREFERRED ACE INHIBITORS

	R	R ₁	R ₂	R ₃	
					$\begin{array}{c} \text{COOR}^1 \quad \text{R}^2 \quad \text{O} \\ \quad \quad \quad \quad \\ \text{R}-\text{CH}-\text{NH}-\text{CH}-\text{C}-\text{R}^3 \end{array}$
spirapril	$\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2^-$	Et	CH ₃		
enalapril	$\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2^-$	Et	CH ₃	prolyl	
ramipril	$\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2^-$	Et	CH ₃		
perindopril	$\text{CH}_3\text{CH}_2\text{CH}_2^-$	Et	CH ₃		
indolapril	$\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2^-$	Et	CH ₃		
lysinopril	$\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2^-$	H	$\text{NH}_2(\text{CH}_2)_4^-$	prolyl	
quinapril	$\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2^-$	Et	CH ₃		
pentopril (NH = CH ₂)	CH ₃	Et	CH ₃		
cilazapril	$\text{C}_6\text{H}_5\text{CH}_2\text{CH}_2^-$	H	$\begin{array}{c} \text{R}^2 \\ \\ \text{CH}-\text{C}-\text{R}^3 \end{array}$		

-22-




<u>R</u>	<u>R</u> ₂
----------	-----------------------


captopril

H



prolyl



zofenopril


 $\text{C}_6\text{H}_5\text{COO}^-$ 

pivalopril



<u>R</u>	<u>R</u> ¹	<u>R</u> ²
----------	-----------------------	-----------------------

fasinopril


 C_6H_5^-

The compounds of the present invention can be produced by methods known to those skilled in the art, for example by one or more of the methods described below. Reactive groups not involved in the condensations described below, e.g., carboxy, etc., may be protected by methods standard in peptide chemistry prior to the coupling reactions and subsequently deprotected to obtain the desired products. In the formulae in the following

-23-

description of the processes, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined above for Formula I, including suitable protection where appropriate.

An acid of formula II can be condensed with an amine of formula III:




wherein R^1 to R^7 , m and n are as defined for formula I. This reaction is well known from peptide chemistry. The reaction can be carried out in the presence of a condensing agent such as 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (DEC), dicyclohexyl-carbodiimide (DCC), diphenylphosphoryl azide (DPPA) or N,N -disuccinimidyl carbonate in an inert solvent such as dimethylformamide. While, as mentioned above, reactive groups are protected before the coupling reaction is carried out, the carboxy group of compound II can be activated via the intermediacy of active esters such as that derived from 1-hydroxybenzotriazole, its mixed anhydride (derived from a chlorocarbonic acid ester) or its azide.


It is evident that a compound of formula I obtained by the above process can be transferred into another compound of formula I by methods known in the art.

The starting compounds in this reaction are known compounds and/or can be prepared according to known methods. The compound of formula II can, for example, be prepared by alkylation of a dianion of formula IV with an electrophilic agent, e.g., a compound of formula V or VI:

-24-



wherein R^1 to R^4 are as defined for formula I and X is halo, alkanesulfonate (e.g. methanesulfonate) or arenesulfonate (e.g. benzyl or tolylsulfonate). Alternatively, the R^2 substituent may be introduced into a compound of formula II(a):



In the above scheme, R^1 to R^4 are as defined for formula I, X is as defined above and suitable bases are strong bases such as lithium diisopropylamide (LDA), sodium hexamethyl disilazide and lithium tetramethyl piperidine. These processes can be carried out in an inert solvent such as THF at temperatures from -78°C to room temperature.

The above processes can be followed by removing protecting groups by known methods. Protected carboxy groups, e.g. when $-\text{OR}^1$ and R^7 are alkoxy (e.g., methoxy, ethoxy, or tert. butyloxy), nitrobenzyloxy or benzyloxy,

-25-

are deprotected by hydrolysis or hydrogenation. Hydrolysis can be carried out under acidic conditions (using e.g. a halogen hydracid or trifluoroacetic acid) or under basic conditions. For example, hydrolysis of a benzyl ester of formula I wherein R⁷ is benzyloxy and R¹ is alkyl will yield compounds of formula I wherein R¹ is alkyl and R⁷ is hydroxy; compounds wherein R⁷ is alkoxy and R¹ is alkyl will yield compounds of formula I wherein R¹ is hydrogen and R⁷ is alkoxy upon acid hydrolysis, and subsequent basic hydrolysis will yield compounds wherein R⁷ is hydroxy.

We have found that the novel compounds of the present invention are effective in treating cardiovascular disorders such as congestive heart failure, edema, renal insufficiency and various types of hypertension, particularly volume expanded hypertension. These novel compounds enhance both the magnitude and duration of the antihypertensive and natriuretic effects of endogenous ANF. Administration of a combination of a carboxyalkylcarbonyl aminoacid and an ACE inhibitor provides an antihypertensive effect greater than either the carboxyalkylcarbonyl aminoacid or ACE inhibitor alone. Administration of a combination of a carboxyalkylcarbonyl aminoacid of formula I and an exogenous ANF or ACE inhibitor is therefore particularly useful in treating hypertension or congestive heart failure.

In addition to the compound aspect, the present invention therefore also relates to treating cardiovascular disorders with a carboxyalkylcarbonyl aminoacid of formula I or with a carboxyalkylcarbonyl aminoacid of formula I in combination with an ANF or an ACE inhibitor, which methods comprise administering to a mammal in need of such treatment an amount of the carboxyalkylcarbonyl aminoacid or an amount of a

-26-

combination of a carboxyalkylcarbonyl aminoacid and ANF or ACE inhibitor effective to treat hypertension, congestive heart failure, edema or renal insufficiency. The drug or combination of drugs is preferably administered in a pharmaceutically acceptable carrier, e.g. for oral or parenteral administration. The combinations of drugs may be co-administered in a single composition, or components of the combination therapy may be administered separately. Where the components are administered separately, any convenient combination of dosage forms may be used, e.g. oral carboxyalkylcarbonyl aminoacid/oral ANF, oral carboxyalkylcarbonyl aminoacid/parenteral ACE inhibitor, parenteral carboxyalkylcarbonyl aminoacid/oral ANF, parenteral carboxyalkylcarbonyl aminoacid/parenteral ACE inhibitor.

When the components of a combination of a carboxyalkylcarbonyl aminoacid and an ANF are administered separately, it is preferred that the carboxyalkylcarbonyl aminoacid be administered first.

The present invention also relates to a pharmaceutical composition comprising a carboxyalkylcarbonyl aminoacid for use in treating hypertension, congestive heart failure, edema or renal insufficiency, to a pharmaceutical composition comprising both a carboxyalkylcarbonyl aminoacid and an ANF and to a pharmaceutical composition comprising both a carboxyalkylcarbonyl aminoacid and an ACE inhibitor.

The antihypertensive effect of carboxyalkylcarbonyl aminoacids was determined according to the following procedure:

Male Sprague Dawley rats weighing 100-150 g were anesthetized with ether and the right kidney was removed. Three pellets containing DOC acetate (desoxycorticosterone acetate, DOCA, 25 mg/pellet) were implanted subcutaneously. Animals recovered from

-27-

surgery, were maintained on normal rat chow and were allowed free access to a fluid of 1% NaCl and 0.2% KCl instead of tap water for a period of 17-30 days. This procedure results in a sustained elevation in blood pressure and is a slight modification of published procedures (e.g. Brock et al., 1982) that have been used to produce DOCA salt hypertension in the rat.

On the day of study, animals were again anesthetized with ether and the caudal artery was cannulated for blood pressure measurement. Patency of the caudal artery cannula was maintained with a continuous infusion of dextrose in water at a rate of 0.2 ml/hr. Animals were placed into restraining cages where they recovered consciousness. Blood pressure was measured from caudal artery catheter using a Statham pressure transducer attached to a Beckman oscillographic recorder. In addition, a cardiovascular monitoring device (Buxco Electronics, Inc.) and a digital computer were used to calculate average blood pressures.

After an equilibration period of at least 1.5 hr., animals were dosed subcutaneously (1 ml/kg) with vehicle (methylcellulose, hereinafter MC) or carboxyalkylcarbonyl aminoacid and blood pressure was monitored for the next 4 hours.

A similar procedure can be used to determine the effect of carboxyalkylcarbonyl aminoacid in combination with ACE inhibitors.

The antihypertensive effect of carboxyalkylcarbonyl aminoacids in combination with ANF can be determined according to the following procedures:

Male spontaneously hypertensive rats (SHR), 16-18 weeks old, 270-350 g, are anesthetized with ether and the abdominal aorta is cannulated through the tail artery. The animals are then placed into restrainers to recover from anesthesia (in less than 10 min.) and remain

-28-

inside throughout the experiments. Through a pressure transducer (Gould P23 series) analog blood pressure signals are registered on a Beckman 612 recorder. A Buxco digital computer is used to obtain mean arterial pressures. Patency of the arterial cannula is maintained with a continuous infusion of 5% dextrose at 0.2 ml/hr. Animals are allowed a 90-min equilibration period. The animals first undergo a challenge with an ANF such as atriopeptin II (AP II) or AP28 30 μ g/kg iv and at the end of 60 min. are treated with drug vehicle or a carboxyalkylcarbonyl aminoacid subcutaneously. A second ANF challenge is administered 15 min. later and blood pressure is monitored for the next 90 min.

The antihypertensive effect in SHR of carboxyalkylcarbonyl aminoacids and ACE inhibitors, alone and in combination, can be determined as follows:

Animals are prepared for blood pressure measurement as described above. After stabilization, animals are dosed subcutaneously or orally with test drugs or placebo and blood pressure is monitored for the next 4 hr.

The compounds having structural formula I have also been found to inhibit the activity of enzymes designated enkephalinases. The compounds are particularly useful for the inhibition of enkephalinase A, which is derived from the striata of both rats and humans. In *in vitro* tests, using test procedures for enkephalinase A inhibition well known to those skilled in the art, selected compounds having structural formula I have been found to inhibit the activity of the aforementioned enzyme. Therefore, the present invention also relates to a method of inhibiting the action of enkephalinases in a mammal thereby to elicit an analgesic effect with a compound of formula I, and to analgesic pharmaceutical compositions comprising compounds of formula I.

-29-

The use of atrial natriuretic peptides in the treatment of nephrotoxicity associated with the immunosuppressive cyclosporin was reported by Capasso et al in the American Journal of Hypertension, 3, (1990), p. 204-210. Since compounds of this invention enhance endogenous ANF, they can be used alone to treat nephrotoxicity, or they can be administered in combination with exogenous ANF.

The compositions of this invention comprise a carboxyalkylcarbonyl aminoacid or a carboxyalkylcarbonyl aminoacid and an ANF or a carboxyalkylcarbonyl aminoacid and an ACE inhibitor in combination with a pharmaceutically acceptable carrier for administration to mammals. A variety of pharmaceutical forms is suitable, preferably for oral or parenteral administration, although mechanical delivery systems such as transdermal dosage forms are also contemplated.

The daily dose of the compound or combinations of this invention for treatment of hypertension, congestive heart failure, edema or renal insufficiency is as follows: for carboxyalkylcarbonyl aminoacids alone the typical dosage is 1 to 100 mg/kg of mammalian weight per day administered in single or divided dosages; for the combination of carboxyalkylcarbonyl aminoacid and an ANF, the typical dosage is 1 to 100 mg of carboxyalkylcarbonyl aminoacid/kg mammalian weight per day in single or divided dosages plus 0.001 to 0.1 mg ANF/kg of mammalian weight per day, in single or divided dosages, and for the combination of carboxyalkylcarbonyl aminoacid and an ACE inhibitor, the typical dosage is 1 to 100 mg of carboxyalkylcarbonyl aminoacid/kg mammalian weight per day in single or divided dosages plus 0.1 to 30 mg ACE inhibitor/kg of mammalian weight per day in single or divided dosages. The exact dose of any component or combination to be administered is determined by the

-30-

attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

Generally, in treating humans having hypertension, congestive heart failure, edema or renal insufficiency, the compounds or combinations of this invention may be administered to patients in a dosage range as follows: for treatment with carboxyalkylcarbonyl aminoacids alone, about 10 to about 500 mg per dose given 1 to 4 times a day, giving a total daily dose of about 10 to 2000 mg per day; for the combination of carboxyalkylcarbonyl aminoacid and ANF, about 10 to about 500 mg carboxyalkylcarbonyl aminoacid per dose given 1 to 4 times a day and about 0.001 to about 1 mg ANF given 1 to 6 times a day (total daily dosage range of 10 to 2000 mg day and .001 to 6 mg/day, respectively); and for the combination of a carboxyalkylcarbonyl aminoacid and an ACE inhibitor, about 10 to about 500 mg carboxyalkylcarbonyl aminoacid per dose given 1 to 4 times a day and about 5 to about 50 mg ACE inhibitor given 1 to 3 times a day (total daily dosage range of 10 to 2000 mg/day and 5 to 150 mg/day, respectively). Where the components of a combination are administered separately, the number of doses of each component given per day may not necessarily be the same, e.g. where one component may have a greater duration of activity, and will therefore need to be administered less frequently.

To produce an analgesic effect, compounds of this invention will be administered in a dosage range of from about 1 to about 100 mg/kg. The doses are to be administered at intervals of from 3 to 8 hours. However, the quantity and frequency of dosage will depend upon such factors as the severity of the pain, the general physical condition of the patient, the age and weight of the patient, and other factors recognized by the skilled clinician.

-31-

For treatment of edema, renal insufficiency or nephrotoxicity associated with immunosuppressive therapy, dosage ranges for the compounds of this invention are the same as for treatment of hypertension with the use of carboxyalkylcarbonyl aminoacids alone or in combination with ANF.

Typical oral formulations include tablets, capsules, syrups, elixirs and suspensions. Typical injectable formulations include solutions and suspensions.

The typical acceptable pharmaceutical carriers for use in the formulations described above are exemplified by: sugars such as lactose, sucrose, mannitol and sorbitol, starches such as cornstarch, tapioca starch and potato starch; cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; calcium phosphates such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinylpyrrolidone, polyvinyl alcohol; stearic acid; alkaline earth metal stearates such as magnesium stearate and calcium stearate, stearic acid, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; non-ionic, cationic and anionic surfactants; ethylene glycol polymers; beta-cyclodextrin; fatty alcohols and hydrolyzed cereal solids; as well as other nontoxic compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavoring agents, and the like commonly used in pharmaceutical formulations.

Since the present invention relates to treatment of hypertension with a combination of active ingredients wherein said active ingredients may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. That is, two kits are contemplated, each combining

-32-

two separate units: a carboxyalkylcarbonyl aminoacid pharmaceutical composition and an ANF pharmaceutical composition in one kit and a carboxyalkylcarbonyl aminoacid pharmaceutical composition and an ACE inhibitor pharmaceutical composition in a second kit. The kit form is particularly advantageous when the separate components must be administered in different dosage forms (e.g. oral and parenteral) or are administered at different dosage intervals.

Following are examples of methods of preparing compounds of formula I.

PREPARATION 1

O-BENZYL-(S)-ISOSERINE ETHYL ESTER pTSA SALT

1. N-(4-Methoxybenzyloxycarbonyl-(S)-isoserine methyl ester: Stir cesium carbonate (6.2 g) and N-(4-methoxybenzyloxycarbonyl-(S)-isoserine (10 g) in dimethyl formamide(DMF) (50 ml) for 1 hr. then add methyl iodide (5.4 g). Stir the resulting mixture for 18 h and concentrate in vacuo. Partition the residue between EtOAc/water and then brine. Concentrate the dried ($MgSO_4$) EtOAc solution in vacuo to give an amber oil. Chromatograph this oil on a column of flash silica gel (1100 ml) using EtOAc:hexane (9:1) as eluant to give an amber oil, $[\alpha]_D^{26} = +16.9^\circ$ (MeOH).

2. N-(4-Methoxybenzyloxycarbonyl-O-benzyl-(S)-isoserine methyl ester: To the product from Step 1, (7.45 g) in anhydrous dimethoxyethane (250 ml), add benzyl bromide (9.3 ml) and silver oxide (9.3 g). Stir the reaction mixture for 72 hr and then heat under reflux for 3 hr. Cool, filter and concentrate in vacuo to give an oil. Chromatograph this oil on flash silica gel (1500

-33-

ml) eluting with EtOAc:hexane 2:18 (4L); 3:17 (4L); 4:16 (8L); 5:15 (4L); 6:14 (4L) and then EtOAc to give a colorless oil, $[\alpha]_D^{26} = -34.6^\circ$ (MeOH).

3. To the product from Step 2 (1.2 g) in absolute EtOH (100 ml), add pTSA•H₂O (1.3 g) and heat the resulting mixture for 4 hr. Add concentrated HCl (5 drops) and heat the resulting mixture for 34 h. Concentrate the mixture in vacuo to give a tan solid, m.p. 148-52°, $[\alpha]_D^{26} = -40.4^\circ$ (MeOH).

EXAMPLE 1

N-[1-(2(R,S)-CARBOXY-4-PHENYLBUTYL)CYCLOPENTANE-CARBONYL]-(L)-METHIONINE

1. 1-(2-t-Butoxycarbonyl-4-phenylbutyl)cyclopentanecarboxylic acid: To diisopropylamine (5.13g, 50.9mmol) in tetrahydrofuran (THF) (20 ml) at -60°C, add n-BuLi hexane solution (20.3ml of 2.5M, 50.9mmol). Warm to 0°C, cool again to -60°C and add cyclopentane-carboxylic acid (2.89g, 25.4mmol). Warm to 0°C for 2.5 hr., cool again and add t-butyl 2-(2-phenylethyl)acrylate (5.90g, 25.4mmol) in THF (10 ml). After 2 h., warm to 0°C, quench with 5N HCl, extract with hexane, wash with 1N NaHCO₃, and concentrate to a solid. Chromatograph on silica, eluting with hexane-ether-HOAc 60:40:1 to obtain an oil.

2. N-[1-(2(R,S)-t-Butoxycarbonyl-4-phenylbutyl)-cyclopentanecarbonyl]-(S)-methionine ethyl ester: Combine the product of Step 1 (1.50g, 4.33mmol) with (S)-methionine ethyl ester hydrochloride (0.92g, 4.33mmol), triethylamine (0.65g, 6.5mmol), hydroxybenzotriazole (HOBT) (0.66g, 4.33mmol), and 1-(3-dimethylaminopropyl)-

-34-

3-ethylcarbodiimide hydrochloride (DEC) (0.91g, 4.8mmol) in 25ml dimethylformamide (DMF). Stir 18 h., partition between EtOAc-H₂O, wash with 1N NaHCO₃ and concentrate. Chromatograph the resultant residue on silica, eluting with hexane-ether 1:1 to obtain an oil, $[\alpha]_D^{26} = -17.4^\circ$ (EtOH).

3. N-[1-(2(R,S)-Carboxy-4-phenylbutyl)cyclopentanecarbonyl]-S-methionine ethyl ester: Add the product of Step 2 (1.0g, 2.0mmol) to trifluoroacetic acid (20ml). After 45 min., concentrate and partition between Et₂O-H₂O. Dry and concentrate to obtain an oil, $[\alpha]_D^{26} = -22.6^\circ$ (EtOH).

4. To the product of Step 3, (0.30g, 0.61mmol) in EtOH (30ml), add 1.0N NaOH (3.0ml). After 2 hr., concentrate, add 1.0N HCl (3.0ml) and extract with EtOAc. Dry and concentrate to obtain the title compound as a solid, $[\alpha]_D^{26} = -5.4^\circ$ (EtOH).

EXAMPLE 2

N-[1-(2-(R,S)-CARBOXY-4-PHENYLBUTYL) CYCLOPENTANE-CARBONYL]- (S)-ISOSERINE

1. N-[1-(2(R,S)-t-Butoxycarbonyl-4-phenylbutyl)-cyclopentanecarbonyl]-S-isoserine ethyl ester: In a fashion similar to that of Example 1, Step 2, combine the product of Example 1, Step 1 with (S)-isoserine ethyl ester p-toluenesulfonate salt to obtain a colorless foam.

2. N-[1-(2(R,S)-Carboxy-4-phenylbutyl)cyclopentanecarbonyl]-S-isoserine ethyl ester: In a fashion similar to that of Example 1, Step 3, treat the product of Step 1 to obtain an oil, $[\alpha]_D^{26} = +8.1^\circ$ (EtOH).

-35-

3. Treat the product of Step 2 in a manner similar to that described in Example 1, Step 4, to obtain the title compound, $[\alpha]_D^{26} = -0.5^\circ$ (EtOH).

EXAMPLE 3

N-[1-[(2(R,S)-CARBOXY)-3-(2-METHOXYETHOXY)PROPYL]-CYCLOPENTANECARBONYL]-(S)-METHIONINE

1. N-[1-[(2(R,S)-t-Butoxycarbonyl)-3-(2-methoxyethoxy)propyl]cyclopentanecarbonyl]-(S)-methionine Ethyl Ester: Combine 3-(1-carboxycyclopentyl)-2-(2-methoxyethoxymethyl)-propanoic acid t-butyl ester (1.50g, 4.6 mmol) with (S)-methionine ethyl ester hydrochloride (0.99 g), N-methylmorpholine (1.0 ml), HOBT (0.71 g), and DEC (1.08 g) in DMF (24 ml). Stir the mixture for 18 hr., concentrate in vacuo, and partition between EtOAc/H₂O, then 0.1N HCl, saturated NaHCO₃, and brine. Concentrate the dried (MgSO₄) EtOAc solution in vacuo to give a light amber oil. Chromatograph the oil on a column of flash silica gel (300 ml) and elute with EtOAc/hexane (1:4) to obtain a colorless viscous oil, $[\alpha]_D^{26} = -26.1^\circ$ (MeOH).

2. N-[1-[(2(R,S)-Carboxy)-3-(2-methoxyethoxy)-propyl]cyclopentanecarbonyl]-(S)-methionine Ethyl Ester: Combine the product of Step 1 (0.8 g) with trifluoroacetic acid (5 ml), thioanisole (0.4 ml), and m-cresol (0.4 ml) in CH₂Cl₂ (15 ml). After 5 hr., concentrate the reaction mixture in vacuo, and chromatograph the resultant residue on silica gel preparative layer plates (10 x 1000 μ) using CH₂Cl₂/MeOH/NH₄OH 170/27/3 as eluant to obtain a viscous oil, $[\alpha]_D^{26} = -26.0^\circ$ (MeOH).

-36-

3. Under a nitrogen atmosphere, dissolve the product of Step 2 (0.42 g, 1.0 mmol) in absolute EtOH (5 ml) and add 1N NaOH (2 ml). After 18 hr., partition the mixture between EtOAc/0.1N HCl (200 ml/500 ml) and then H₂O. Concentrate the dried (MgSO₄) EtOAc in vacuo to obtain the title compound as a colorless oil, $[\alpha]_D^{26} = -15.9^\circ$ (MeOH).

EXAMPLE 4

N-[1-[2(R,S)-CARBOXY]-3-(2-METHOXYETHOXY)PROPYL]-CYCLOPENTANECARBONYL]- β -ALANINE BENZYL ESTER

1. N-[1[2(R,S)-(t-Butoxycarbonyl)-3-(2-methoxyethoxy)propyl]cyclopentyl-1-carbonyl- β -alanine Benzyl Ester: Substitute β -alanine benzyl ester p-TSA salt (1.62 g) for the methionine ester in the procedure of Example 3, Step 1, eluting the silica gel with EtOAc/hexane (6:14) to obtain a colorless oil, M⁺ 491.

2. Treat the product of Step 1 (1.33 g) with trifluoroacetic acid (5 ml) in CH₂Cl₂ (15 ml). After 1.5 hr., concentrate the reaction mixture in vacuo, and chromatograph the residue on flash silica gel using CH₂Cl₂/MeOH/NH₄OH 170/27/3 as eluant and on silica gel preparative layer plates (12 x 1000 μ) using CH₂Cl₂/MeOH/NH₄OH 170/27/3 as eluant to obtain the title compound as a viscous oil.

-37-

EXAMPLE 5

N-[1-[(2(R,S)-CARBOXY)-3-(2-METHOXYETHOXY)PROPYL]-CYCLOPENTANECARBONYL]-(S)-ISOSERINE BENZYL ESTER

1. N-[1-[(2(R,S)-t-Butoxycarbonyl)-3-(2-methoxyethoxy)propyl]cyclopentanecarbonyl]-(S)-isoserine Benzyl Ester: In a manner similar to that described in Example 3, Step 1, substitute (S)-isoserine benzyl ester hydrochloride for the methionine compound and elute the silica gel with EtOAc/hexane (7:13) to obtain a colorless oil, $[\alpha]_D^{26} = +10.4^\circ$ (MeOH).
2. Treat the product of Step 1 (1.04 g) with trifluoroacetic acid (20 ml) in CH_2Cl_2 (20 ml). After 18 hr., concentrate the reaction mixture in vacuo, and chromatograph the residue on silica gel preparative layer plates (12 x 1000 μ) using $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ 170/27/3 as eluant to obtain the title compound as a viscous oil, $[\alpha]_D^{26} = +8.1^\circ$ (MeOH).

EXAMPLE 6

N-[1-[2(R,S)-CARBOXY-3-(2-METHOXYETHOXY)PROPYL]-CYCLOPENTANECARBONYL]-O-BENZYL-(S)-ISOSERINE

1. N-[1-[2(R,S)-(t-Butoxycarbonyl)-3-(2-methoxyethoxy)propyl]cyclopentanecarbonyl]-O-benzyl-(S)-isoserine ethyl ester: Substitute O-benzyl-(S)-isoserine ethyl ester p-TSA salt (0.75 g) for the methionine ester in the procedure of Example 3, Step 1, and elute the silica gel with EtOAc/hexane (1:3) to obtain a colorless oil, $[\alpha]_D^{26} = -21.7^\circ$ (MeOH).

-38-

2. N-[1-[2(R,S)-Carboxy-3-(2-methoxyethoxy)-propyl]cyclopentanecarbonyl]-O-benzyl-(S)-isoserine ethyl ester: Treat the product of Step 1 (0.60 g) with trifluoroacetic acid (10 ml) in CH_2Cl_2 (10 ml). After 0.5 hr., concentrate the reaction mixture in vacuo to give a colorless oil, $[\alpha]_D^{26} = -23.8^\circ$ (MeOH).

3. In a manner similar to that described in Example 3, Step 3, substitute the product from Step 2 above (0.271 g) for the methionine compound to give the title compound as a viscous colorless oil, $[\alpha]_D^{26} = -37.8^\circ$ (MeOH).

The following formulations exemplify some of the dosage forms of the compositions of this invention. In each, the term "active compound" designates a compound of formula I, preferably N-[1-(2-carboxy-4-phenylbutyl)-cyclopentanecarbonyl]-(S)-isoserine. However, this compound may be replaced by equally effective amounts of other compounds of formula I.

Pharmaceutical Dosage Form Examples

Example A

Tablets

<u>No.</u>	<u>Ingredient</u>	<u>mg/tablet</u>	<u>mg/tablet</u>
1	Active Compound	100	500
2	Lactose USP	122	113
3	Corn Starch, Food Grade, as a 10% paste in Purified Water	30	40
4	Corn Starch, Food Grade	45	40
5	Magnesium Stearate	3	7
	Total	300	700

-39-

Method of Manufacture

Mix Item Nos. 1 and 2 in suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weight on a suitable tablet machine.

Example B

Capsules

<u>No.</u>	<u>Ingredient</u>	<u>mg/capsule</u>	<u>mg/capsule</u>
1.	Active compound	100	500
2.	Lactose USP	106	123
3.	Corn Starch, Food Grade	40	70
4.	Magnesium Stearate NF	4	7
	TOTAL	250	700

Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

-40-

Example C

Parenteral Preparation


<u>Ingredient</u>	<u>mg/vial</u>	<u>mg/vial</u>
Active Compound Sterile Powder	100	500

For reconstitution add sterile water for injection or
bacteriostatic water for injection.

-41-

We Claim:

1. A compound represented by the formula



wherein R^1 is H, alkyl, arylalkyl, aryl or aryloxyalkyl; R^2 is alkyl, alkenyl, alkynyl, alkoxy or alkylthio, wherein the alkyl portion is substituted with 0-3 substituents independently selected from the group consisting of hydroxy, alkoxy, alkoxyalkoxy, alkylthio, aryl, alkoxyalkylthio, arylalkoxy and arylalkylthio;

R^3 and R^4 are independently alkyl or arylalkyl; or R^3 and R^4 together with the carbon to which they are attached form a 5-, 6- or 7-membered ring wherein said ring comprises 0 to 1 heteroatoms selected from the group consisting of sulfur and oxygen, wherein said ring is unsubstituted or is substituted on a carbon atom ring member by an alkyl or aryl group, or wherein said ring is substituted by a fused benzene ring;

R^5 is H, alkyl, alkoxyalkyl, alkylthioalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylalkoxyalkyl or arylalkylthioalkyl;

R^6 is H, hydroxy, alkoxy, alkyl, arylalkoxy, alkoxyalkyl, alkylthioalkyl, arylalkoxyalkyl, arylalkylthioalkyl, aryl or heteroaryl;

R^7 is hydroxy, alkoxy, aryloxy, arylalkoxy, amino, alkylamino or dialkylamino;

-42-

m is 0 or 1;

n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein R² is arylalkyl or alkoxyalkoxyalkyl.

3. A compound of claim 2 wherein R³ and R⁴ together with the carbon to which they are attached form a carbocyclic 5-, 6- or 7-membered ring.

4. A compound of claim 1 or 3 wherein R⁵ is hydrogen, R⁶ is hydroxy or hydrogen, m is 1 and n is zero.

5. A compound of claim 1 or 3 wherein R⁶ is alkylthioalkyl and m and n are each zero.

6. A compound of claim 1 wherein R¹ is hydrogen and R⁷ is hydroxy or benzyloxy.

7. A compound of claim 1 which is:

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(L)-methionine;

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(L)-methionine ethyl ester;

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(S)-isoserine;

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(S)-isoserine ethyl ester;

N-[1-(2-carboxy)-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]-(S)-methionine;

N-[1-(2-carboxy)-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]-(S)-methionine ethyl ester;

-43-

N-[1-[2-carboxy-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]- β -alanine benzyl ester;
N-[1-[2-carboxy-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]- (S) -isoserine benzyl ester;
N-[1-(2-carboxy)-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]-O-benzyl- (S) -isoserine ethyl ester;
N-[1-(2-carboxy)-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]-O-benzyl- (S) -isoserine.

8. A pharmaceutical composition for treating hypertension, congestive heart failure, edema, renal insufficiency, nephrotoxicity or pain comprising an effective amount of a compound of claim 1, alone or in combination with an atrial natriuretic factor or an angiotensin converting enzyme inhibitor in a pharmaceutically acceptable carrier.
9. A composition of claim 8 wherein the atrial natriuretic peptide is chosen from α human AP 21, α human AP 28, α human AP 23, α human AP 24, α human AP 25, α human AP 26, α human AP 33, and the corresponding atrial peptides wherein the methionine at position 12 is replaced by isoleucine.
10. A composition of claim 8 wherein the angiotensin converting enzyme inhibitor is selected from: spirapril, enalapril, ramipril, perindopril, indolapril, lysinopril, quinapril, pentopril, cilazapril, captopril, zofenopril, pivalopril and fosinopril.
11. A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to treat hypertension, congestive heart failure or nephrotoxicity in mammals which comprises in

-44-

one container a pharmaceutical composition comprising a carboxyalkylcarbonyl aminoacid of claim 1 and in a second container a pharmaceutical composition comprising an atrial natriuretic factor.

12. A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to treat hypertension or congestive heart failure in mammals which comprises in one container a pharmaceutical composition comprising a carboxyalkylcarbonyl aminoacid of claim 1 and in a second container a pharmaceutical composition comprising an angiotensin converting enzyme inhibitor.

13. A method for treating hypertension, congestive heart failure, edema, renal insufficiency, nephrotoxicity or pain in mammals comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1 alone or in combination with an atrial natriuretic factor or an angiotensin converting enzyme inhibitor.


14. A method for preparing a pharmaceutical composition comprising admixing a compound of claim 1 with a pharmaceutically acceptable carrier.

15. The use of a compound of claim 1 for the manufacture of a medicament for treating hypertension, congestive heart failure, edema, renal insufficiency, nephrotoxicity or pain.

16. A process for the preparation of a compound of formula I as defined in claim 1, wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , m and n are as defined in claim 1, including suitable protection, comprising condensation of an acid

-45-

of formula II or a reactive derivative thereof with an amine of formula III:




followed by isolation of the preferred isomer, if desired, and removal of the protecting groups, if necessary, to yield the desired product, and if desired, preparation of a salt thereof.

-46-

AMENDED CLAIMS

[received by the International Bureau
on 24 April 1991 (24.04.91);
original claims 1 and 4 amended;
other claims unchanged (2 pages)]

1. A compound represented by the formula



wherein R^1 is H, alkyl, arylalkyl, aryl or aryloxyalkyl;
 R^2 is alkyl, alkenyl, alkynyl, alkoxy or alkylthio,
wherein the alkyl portion is substituted with 0-3
substituents independently selected from the group
consisting of hydroxy, alkoxy, alkoxyalkoxy, alkylthio,
aryl, alkoxyalkylthio, arylalkoxy and arylalkylthio;

R^3 and R^4 are independently alkyl or arylalkyl; or R^3 and
 R^4 together with the carbon to which they are attached
form a 5-, 6- or 7-membered ring wherein said ring
comprises 0 to 1 heteroatoms selected from the group
consisting of sulfur and oxygen, wherein said ring is
unsubstituted or is substituted on a carbon atom ring
member by an alkyl or aryl group, or wherein said ring is
substituted by a fused benzene ring;

R^5 is H, alkyl, alkoxyalkyl, alkylthioalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, arylalkoxyalkyl
or arylalkylthioalkyl;

R^6 is H, hydroxy, alkoxy, alkyl, arylalkoxy, alkoxyalkyl,
alkylthioalkyl, arylalkoxyalkyl, arylalkylthioalkyl, aryl
or heteroaryl; provided that when R^3 and R^4 form a ring,
 m is 1 and n is zero, R^5 and R^6 are not both hydrogen;
 R^7 is hydroxy, alkoxy, aryloxy, arylalkoxy, amino,
alkylamino or dialkylamino;

m is 0 or 1;

n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein R² is arylalkyl or alkoxyalkoxyalkyl.

3. A compound of claim 2 wherein R³ and R⁴ together with the carbon to which they are attached form a carbocyclic 5-, 6- or 7-membered ring.

4. A compound of claim 1 or 3 wherein R⁵ is hydrogen, R⁶ is hydroxy, m is 1 and n is zero.

5. A compound of claim 1 or 3 wherein R⁶ is alkylthioalkyl and m and n are each zero.

6. A compound of claim 1 wherein R¹ is hydrogen and R⁷ is hydroxy or benzyloxy.

7. A compound of claim 1 which is:

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(L)-methionine;

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(L)-methionine ethyl ester;

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(S)-isoserine;

N-[1-(2-carboxy-4-phenylbutyl)cyclopentane-carbonyl]-(S)-isoserine ethyl ester;

N-[1-(2-carboxy)-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]-(S)-methionine;

N-[1-(2-carboxy)-3-(2-methoxyethoxy)propyl]-cyclopentanecarbonyl]-(S)-methionine ethyl ester;

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/06655

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁵ : C 07 C 323/59, C 07 C 235/40, C 07 C 233/63		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	C 07 C 323/00, C 07 C 235/00, C 07 C 233/00	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. 13
X	Biochemical and Biophysical Research Communications, vol. 164, no. 1, 16 October 1989, Academic Press, Inc., J.C. Danilewicz et al.: "UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic", pages 58-65 see page 60, scheme I, compound no. 4	1-4,6,8,14-16
A	WO, A, 8600066 (CIBA-GEIGY) 3 January 1986 see example; claims cited in the application	1-12,14-16
A	EP, A, 0038046 (WELLCOME) 21 October 1981 see examples; claims cited in the application	1-12,14-16
	. / .	
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
21st February 1991	20.03.91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Hans-Joachim Weinberg	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A EP, A, 0358398 (PFIZER)
 14 March 1990
 see the whole document
 cited in the application

1-12,14-16

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers ...13... because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv):

Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

The additional search fees were accompanied by applicant's protest.
 No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 9006655
SA 42400

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 15/03/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A- 8600066	03-01-86	AU-B-	594645	15-03-90
		AU-A-	4607085	10-01-86
		DE-A-	3565677	24-11-88
		EP-A, B	0185079	25-06-86
		JP-T-	61502468	30-10-86
		US-A-	4939261	03-07-90
EP-A- 0038046	21-10-81	GB-A, B	2074571	04-11-81
		JP-A-	56158746	07-12-81
EP-A- 0358398	14-03-90	AU-B-	604195	06-12-90
		AU-A-	4105289	08-03-90
		JP-A-	2124862	14-05-90

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82